Interleukin-2 Family Members and their Role in Demyelinating Disease

Bhopale MK*
Department of Microbiology, R.D. Gardi Medical College, India

*Corresponding author: Mahendra K. Bhopale, Ph.D., D.Sc, Department of Microbiology & Director (Research), R.D. Gardi Medical College, Ujjain, MP 456001, India, Tel: +91-7368-261235; Email: mbhopale@yahoo.com

Abstract

Interleukin-2 (IL-2) has a family which includes IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 cytokines. This family group of an IL-2 cytokine plays important, but different roles in neurologically related demyelinating disease studied in multiple sclerosis (MS) and it's experimentally induced rodent models. IL-2 play role in strong T-cell expansion and participates in the maintenance of T-reg cells, but also keep in the stimulation and proliferation of pathogenic T cells. IL-4 induces differentiation of naïve helper T cells (Th0) to Th2 cells. IL-7 promotes Th1 cell differentiation. IL-9 is a hematopoietic growth factor for major pathogenic Th17 cells in EAE. IL-15 is necessary for memory CD8+ T cells and plays a negative regulatory role through CD8+ CD122+ T cells in reducing Th17-mediated inflammation. IL-21 has potent regulatory effects on the natural killer (NK) cells and cytotoxic T cells. IL-21 activates CD4+ and up-regulates the Th2 and Th17 subsets of T helper cells. Based on different roles of each family member in demyelinating disease, bio-agents and therapeutic agents have been attempted in an experimental model to study their role in demyelinating disease is described in the present review.

Keywords: Multiple Sclerosis; Experimental Autoimmune Encephalomyelitis; Demyelinating Disease; Role of IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 Cytokines; Drugs; Bio-agents; Immune Response; Therapy

Introduction

Multiple sclerosis (MS) is a demyelinating disease in humans. This disease is an inflammatory disorder of the brain and spinal cord in which focal lymphocytic infiltration leads to loss and dysfunction of myelin and axons. Experimental autoimmune encephalomyelitis (EAE) serves as an animal model of MS, is used to study the clinical and pathological criteria to evaluate the effect of drugs and bio-agents by cytokine changes as potential therapeutic interventions.
In acute and relapsing MS patients, the disease response is contingent upon activating effector phenotype CD4+ and CD8+ T cells. CD4+CD25hi regulatory T cells demonstrated due to the CD4 cells IL-2 responsiveness in demyelinating disease. Interferon-γ secreting cells and T-lymphocyte subtypes play an important role in activating interleukin-17 under interleukin-23 control.

Interleukin-2 is a member of a family which includes IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 [1]. IL-2 cytokine plays an important role in Th1 and Th17 regulation whereas CD4+FoxP3+ regulatory T cells (Tregs) down-regulate the immune response. MS patients possess either a lower frequency of Tregs or impairment in their suppressor function, promotes disease development [2]. Based on their cytokine production, CD4+ T cells is divided into two helper lineages known as Th1 and Th2 cells. Th1 cells, which produce IFN-γ, mediate inflammation in the CNS while Th2 cells produce IL-4 in demyelinating disease. IL-2 participates in the maintenance of T-reg cells and reduces self-reactive T cells. Th17 cells play in the pathogenesis of demyelination is known as Th17/Th1 paradigm [3].

IL-2 has a similar function as IL-15, enhances activity of CD8+ cells and induces CD8+CD44hi memory T cells. IL-15 stimulates B cells and dendritic cells but does not stimulate T regulatory cells (Tregs). There are primary differences between IL-2 and other family member like IL-9, which enhance regulatory CD4 (+) FoxP3 (+) T regulatory (Treg) cell survival and T helper 17 (Th17) cell proliferations. On the other hand, IL-21 activates immunoregulatory circuit that is important in the modulation of the course of the autoimmune disease. IL-21 shares sequence homology with IL-2 and the IL-21 receptors contain a gamma-chain common to IL-2. IL-21 also affects the homeostasis of Tregs [4].

It is an important study to understand the mechanisms of immune-mediated destruction or repair CNS components in the experimental models of MS and to provide each IL-2 family member playing an individual role in the immune system in demyelinating disease to present effective design of therapeutics in the review.

**Interleukin-2**

Interleukin-2 (IL-2) is a type of cytokine singling molecule in the immune system that regulates the activities of leukocytes and lymphocytes for immunity. The IL-2 receptor complex consists of IL-2 receptor alpha (CD25), IL-2 receptor beta (CD122) and a common gamma chain (γc) (CD132) is shared by all members of this family. IL-2R is comprised of three distinct non-covalently linked chains known as α CD25, IL-2α subunit does not participate in signaling. In IL-2, beta chain with Janus kinase 1 (JAK1) is capable of adding phosphate groups, whereas gamma chain complexes with tyrosine kinase known as JAK3. CD4+T cells regulate effective immune response to pathogens. Naive CD4+T cells activate after interaction with antigen-MHC complex and differentiate into specific subtypes depending on the cytokine milieu of the microenvironment. Besides the classical T-helper 1 and T-helper 2, other subsets identify as T-helper 17, regulatory T cell, follicular helper T cell, and T-helper 9 and each characterize with a cytokine profile [5].

IL-2 plays role in T-cell activation, Treg induction, NK-cell activation and DC differentiation. IL-2 activates Th1 and Th17 T-cells, which produce a series of pro-inflammatory cytokines [6]. MAPK pathways regulate T cell activation, differentiation, effector function, apoptosis and development [7]. Ikzf4 transcription factors, plays an important role in IL-2 and Th17 production by CD4+ T cells and maintains the Treg stability and effector T cell [8].

Regulatory T- cells (Tregs) express IL-2 receptors (IL-2Rs) which play an important role in preventing the development of autoimmunity. IL-2 and Tregs have been demonstrated in eliciting immune response and preventing autoimmunity with neurotrophic factors function in remyelination [9,10]. CD25 regulatory T cells determine secondary remission, but not a primary clinical episode of disease in EAE. The first remission occurred even after depletion of Treg cells, but secondary remissions from EAE are ablated [11]. It is known that IL-17-producing CD4 cells in the CNS have the pathogenic role of an independent (non-Th1) IL-17-producing pro-inflammatory effector T cells and IL-17-producing pro-inflammatory effector T cell class in EAE [12]. On the other hand, B cells participate in the regulation of CNS autoimmune disease through the production of auto-antibodies. Adoptive transfers of myelin-specific CD4+ Th1 cells into naïve recipient mice promote the induction of EAE [13,14].

**IL-2 role in therapy** IL-2 recombinant fusion protein, known as a DAB_389IL-2 target IL-2R bearing CD4+ cells is attempted in EAE rodent models. DAB_389IL-2 suppresses at the early time points, but negative consequences at later time points. DAB_389IL-2 directly targets CD4+ and CD25+, IL-2R T cells and effector T cell function [15,16]. DAB_389IL-2 indirectly suppresses the activation of macrophage CD169+ (ED3+) and microglia CD11b/c (OX42+) populations in the CNS. DAB_389IL-2 also reduce CD3+CD4+, CD3+CD8+, CD4+CD8+, CD3*IL-2*, CD3*IFN-γ*, CD3*TNF-α*, CD3*CD25* cell subpopulations [17,18]. However, DAB_389IL-2 also exhibit toxic side effect. IL-2-caspase-3, another chimeric protein, is designed to target and kill cells expressing the high affinity IL-2 receptor. IL-2-caspase-3 chimeric protein treatment to EAE-induced mice results a significant delay in disease with a reduction in disease symptoms [19].
There is another fusion protein known as interleukin-2/neoantigen (NAg) fusion protein is studied in the EAE model. IL2NAg (IL-2/NAg fusion protein) injection in Lewis rats results in suppression of encephalitogenic disease. It shows an increased Tregs activity with low-dose IL-2 immunotherapy that prevents the development of T-follicular helper CD4+ T-cell subset promoting long-term effector B-cell responses in autoimmune disease patients [20]. Daclizumab is a humanized monoclonal antibody CD25 alpha subunit of the high-affinity interleukin (IL)-2 receptor, reduce IL-2-mediated lymphocyte activation and up regulation of CD56-bright natural killer cells in relapsing-remitting multiple sclerosis [21].

FSD-C10 is a Fasudil derivative which reduces the severity through the modulation of the immune response by induction of neuroprotective molecules in the CNS in EAE. Intranasal delivery of FSD-C10 effectively ameliorates the induction of neuroprotective molecules in the CNS in EAE [22]. T cell cytokine production alteration has been observed in EAE mice by using immunostimulatory CpG oligonucleotide. CpG can have different effects on T cell cytokine production depending on whether they are present in the priming phase or during the ongoing autoimmune response, the effects differ qualitatively and quantitatively in the inflamed CNS [23]. B cells participate in the pathogenesis and regulation of CNS autoimmune disease has been found through the production of auto-antibodies. The auto antigen-specific B cell lineage leads to production of the pathogenic autoantibodies. These auto antigen-specific B cells have been consistently identified in the circulation with high serum levels of auto antigen-specific antibodies [24].

Other reports show that interleukin-2 (IL2) repressor genes ZEB1 influence T cell regulation. ZEB1 affect the regulation, novel pathways to contribute pathogenesis and inflammation in EAE [25]. Neuropilin-1 (Nrp1) has been implicated in several aspects of immune function, including maintenance of the immune synapse and development of regulatory Treg cells [26]. CD4+ T-cell activates trafficking regulating by Itk signals and promotes neuroinflammation. Itk−/−CD4+ T cells show significant reduction in the production of T-helper 1 (Th1) and Th17 cytokines [27]. Immune modulation of IL-2 receptor restores impaired immune regulation by increasing the proportion of CD155-expressing CD4 (+) T cells and the cytolytic activity of NK cells in MS [28].

**Interleukin-4**

The interleukin 4 (IL-4) is a cytokine that induces differentiation of naïve helper cells (Th0) to Th2 cells. IL-4 receptor composed of IL-4 α of a subunits bind with a common γ chain. IL-4 activate by the JAK1 and JAK3 signaling transducer of STAT6. IL-4 receptor-mediated STAT5 activation is dependent on the presence of γc and JAK3 receptor complex. IL-4 decreases the production of Th1 cells, macrophages, IFN-γ and dendritic IL-12.

CNS-derived IL-4 is a critical regulator in mice with a deficiency in IL-4 production in the CNS with a significant increase in the absolute number of infiltrating inflammatory cells. It induces a state of alternative activation in microglial cells [29]. CNS-resident microglial cells in both the resting and activated state produced the protein Ym1, which is a marker of alternatively activated macrophages in an IL-4-dependent manner. Th2 cytokines IL-4 and IL-5 regulate serum production, which effects on regulatory T cell expression of Foxp3 and suppressing the production of proinflammatory cytokines in EAE [30].

**IL-4 role in therapy** There are studies related IL-4 involvement in therapy. For example, the combination of methylprednisolone (MP) and human bone marrow-derived mesenchymal stem cells (BM-MSCs) reduce proinflammatory cytokines (IFN-γ, TNF-α, IL-17) and enhanced anti-inflammatory cytokines (IL-4, IL-10). Treatment with dimethyl fumarate (DMF) reduces the severity of EAE in mice and the relapse rates of MS in humans. DMF promotes an IL-23+IL-12−IL-10−DC phenotype and its efficacy is mainly explained by a suppression of encephalitogenic Th17/Th1 cells and an induction of IL-4/Th2 cells. Dimethyl fumarate promotes an IL-17AlowIFN-γlowIL-4CD4+T cell phenotype. DMF-treated myelin peptide-reactive IL-17AlowIFN-γlowIL-4CD4+T cells prior to immunization in donors of donor cells from UTZ fed mice [31]. The drug, Ustekinumab (UTZ) (Stelera®), oral administration decreased proinflammatory cytokines Th1-like cytokines IL-2, IL-12, IFN-γ, IL-17 (Teff) and increased counter-regulatory cytokines IL-4, IL-10 and IL-13 in recipients of donor cells from UTZ fed mice [32]. Another drug, N1rp12 plays a protective role by suppressing inflammation altered NF-xB regulation and IL-4 production during the development of EAE [33,34].

The suppressive effect of myelin basic protein (MBP) peptide 68–86 in the EAE Lewis rats, ameliorate the disease with decreased infiltration of ED1+ macrophages and CD4+ T cells within the central nervous system [35]. Interestingly, mesenchymal stem/stromal cells (MSCs) therapy has considerable promise for tissue regeneration. MSCs-IFNβ reduces migration into the inflammatory cells in the CNS of EAE mice. Bone marrow-derived mesenchymal stem cells (BM-hMSCs) induce Th2-polarized immune response interferon gamma (IFN-γ) producing Th1 cells and IL-17 producing Th17 inflammatory cells increases in IL-4 producing Th2 cells [36–38].

**Interleukin-7**

Interleukin-7 (IL-7) cytokine plays an important function in T-cell development and memory cell induction. IL-7 is a hematopoietic growth factor, secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, hepatocytes, neurons, endothelial cells but not by lymphocytes. IL-7 stimulates and differentiates pluripotent hematopoietic stem cells proliferate all lymphoid lineage B cells, T cells and NK cells. IL-7 is genetically associated with susceptibility to demyelinating disease in multiple sclerosis. IL-7R consists of two subunits, interleukin-7 receptor-α (CD127) and common-γ chain receptor (CD132). The IL-7/IL-7R signaling axis perturbation is associated with enhanced susceptibility to MS. IL-7 is an essential for survival of pathogenic Th17 cells. IL-7R antagonism differentiates Th17 cells through the inhibition of JAK-STAT5 pathways, brings alteration in Bcl-2 and Bax proteins, which decrease severity of disease in EAE. The role of IL-7-IL-7R in Th17 cell survival implicates in the treatment of autoimmune disease [39].

A progressive enrichment for CD4 single-positive Foxp3 (+) regulatory T cells is characterized by accelerating differentiation and proliferation of regulatory T (Treg) cells. Stromal cells increase expression through a mechanism involves IL-7. IL-17-producing CD4 (+) T (Th17) cells, along with IFN-γ-expressing Th1 cells, represent two major pathogenic T cell subsets in EAE. There is a link between IL-23-driven pathogenic T cells and IL-7/IL-7R signaling. IL-7 inhibits the differentiation of Th17 cells.

**IL-7 role in therapy** IL-7α alters T cell and non-hematopoietic cell lineages response in EAE. IL-7Rα expression is identified on astrocytes and oligodendrocytes endogenous to the CNS. IL-7α-blocking antibodies before or after onset of paralysis exhibits reduction in clinical signs and also activation of regulatory T cells and B cells, and natural killer cell with markedly reduces lymphocyte infiltration into the central nervous system confers Th1/Th17 responses in the EAE [40]. IL-7 activates GM-CSF produces CD4+ T cells by STAT5 to induce more severe EAE than Th17 or Th1 cells [41]. The effect of CD127 blockade has also been observed in an inbred/SPF mouse EAE model in a positive response to the treatment. IL-7 signaling is a prerequisite for optimal CD4+ T cell activation that IL-7R antagonism effective in treating CD4+ T cell-mediated neuroinflammation [42,43]. MS patients have lower serum IL-7 and a higher membrane IL-7Rα expression in CD56 bright NK cells [44]. IL-7 bioactivity provides a basis to explain the increased risk of autoimmune genotype-induced elevations of sIL7Rα [45]. Serum profile of high IL-7 signifies a TH1-driven form of MS in IFN-β therapy and blockade of IL-7 and the IL-7Rα pathway have therapeutic potential in MS and other autoimmune diseases [46]. Blocking IL-7 signaling in myelin-specific CD4 T cells by αIL-7Rα significantly delays EAE onset and reduces disease severity. The IL-7Rα expression suppresses the encephalitogenic potential of myelin-specific CD4 T cells and has therapeutic benefits. IL-7Rα confers susceptibility by influencing autoimmune Th1/Th17 responses in the EAE model [47,48].

Interferon-β is the major treatment for multiple sclerosis (MS). However, this treatment is not always effective. Here we see congruence in outcome between responses to IFN-β in experimental autoimmune encephalomyelitis (EAE) and relapsing-remitting MS (RRMS). IFN-β is effective in reducing EAE induced by Th1 cells, but exacerbated disease induced by Th17. T helper 1 (Th1)-driven, but not a Th17-driven, form of MS exhibited a good clinical response to interferon-β (IFN-β) therapy. Blocking IL-7 signaling in myelin-specific CD4+ T cells by αIL-7Rα significantly delays EAE onset and reduces disease severity [49,50].

**Interleukin-9**

Interleukin 9 (IL-9) cytokine plays important role in T-cell activation and mast cell activation. IL-9 is a dominant cytokine in Th9 cells, has been proven to play a pathogenic role in the EAE model by augmenting T cell activation and differentiation. The IL-9 receptor complex is shared by γ subunit of IL-2Rγ. The ligand receptor binding of IL-9 leads to the activation of various JAK kinase and STAT proteins for different biological responses [51]. IL-9 is a cell signaling protein molecule encoded by CD4+ helper cells. IL-9 is a hematopoietic growth factor as a mediator of Th17 cells. IL-9 receptor (IL-9R) is highly expressed in astrocytes, oligodendrocyte progenitor cells, oligodendrocytes and microglia cells in the brain and spinal cord during EAE [52]. In MS and EAE, microglia induce different effector functions that can be both neuroprotective and detrimental. Currently, it is believed that the initial response of microglia is beneficial, but the chronic activation of microglia contributes to neurodegeneration [53].

Myelin oligodendrocyte glycoprotein (MOG)-specific effector T cell subsets (Th1, Th17 and Th9) can induce EAE independently of each other. They all produce different cytokines and the inflammatory process advances. However, the clinical disease manifestations are indistinguishable [54]. A new effector T subset Th9 cells are identified as myelin oligodendrocyte glycoprotein-specific Th1, Th17, and Th9 but not Th2 cells in EAE upon adoptive transfer. Th9 cells are a newly discovered CD4+ T helper cell subtype, characterized by high interleukin (IL)-9 secretions. Growing evidences suggest that Th9 cells participate in the pathogenic mechanism of multiple sclerosis (MS). There is dynamic “crosstalk” between Th9 and mast cells. IL-9-mast cell axis in EAE also determines its interaction after neutralizing
anti-IL-9 antibody. IL-9 blockade using anti-IL-9 antibody treatment ameliorates EAE with decreasing in mast cell infiltration in CNS [55].

**IL-9 role in therapy** IL-9 is seen in the context of T_h2-associated inflammatory conditions in allergic inflammation. IL-9 is considered just another T_h2 cytokine and thought to be redundant among other T_h2 cytokines (i.e. IL-4, IL-5 and IL-13). IL-9 seems to be one cytokine of many sources, and therefore, interest in IL-9 biology and in its significance. The role of T_h9 supporting a role for T_h9 cells in EAE, suggesting that targeting T_h9 cells may provide an additional approach in the treatment of such autoimmune conditions. There are other conditions where promotion of T_h9 cells may therapeutically beneficial.

The protective effect of anti-IL-9 mAb treatment in EAE is mediated not only via suppression of IL-9-induced inflammatory reactions, but also via inhibition of the induction of MOG_{1-55}-peptide-specific Th17 and Th1 cells, which in turn leads to reduced infiltration of T cells into the CNS. This study evidence for an important pathogenic role of IL-9 in EAE and also indicate that anti-IL-9 mAb treatment represent a therapeutic agent. Further, anti-IL-9 mAb immunization with myelin proteolipid protein (PLP180-199) peptide in Complete Freund’s Adjuvant (CFA) exhibit considerably fewer infiltrating immune cells in the CNS and also suppress IL-17 and IFN-γ expression. IL-9 affects Th17 cells not only through the activation of STAT3, but also STAT1, suggesting that IL-9 triggers complex STAT signaling pathways. IL-9 control pathways central to the induction and development of EAE whereas disruption of the IL-9 gene reduces inflammatory infiltrates in the CNS and attenuates clinical symptoms of EAE [56].

**Interleukin-15**

Interleukin-15 (IL-15) is a cytokine with structure similar to IL-2. IL-15 is an inflammatory cytokine. IL-15 binds through the signaling pathway of IL-15Ra receptor and IL-15β subunit through the activation of Jak1 and Jak2 in yc subunit with the help of STAT3 and STAT5. The role of IL-15 is STAT5 activation and IL-17A production in CD4 T lymphocytes. Th17 cells play critical roles as a negative regulatory role in reducing Th17-mediated EAE inflammation through CD8+ CD122+ T cells [57].

The role of T regulatory cells (T_reg) has been demonstrated to be capable of controlling CNS autoimmunity in several EAE models. Transfer of CD25+ T_reg ameliorated EAE symptoms. In addition, non-specific ablation of natural T_reg by anti-CD25 antibodies has been reported to exacerbate EAE. Furthermore, T_reg have been shown to prevent spontaneous EAE development or delay spontaneous EAE onset [58]. This indicates that IL-15 has a negative regulatory role in fine-tuning of IL-17A production and Th17-mediated inflammation.

**IL-15 role in therapy** Interleukin (IL)-15 can cross the blood-brain barrier to act on its specific brain receptor (IL15Rα) and co-receptors. The important roles of neuronal IL-15 and IL15Rα in EAE are suggested by the up-regulation of IL15Rα in different regions of the brain and spinal cord. Contrary to expectations, IL-15 treatment lessened EAE severity. IL-15 knockout mice showed heightened susceptibility to EAE with significantly higher scores that were decreased by treatment with IL-15. IL-15 improves the CNS autoimmune disorder as a potential therapeutic agent.

Interleukin 15 (IL-15) expression induces the secretion of inflammatory cytokines, inhibits the apoptosis of activated T cells and prolongs the survival of CD8+ memory T cells. An IL-15 isoform is a natural antagonist for IL-15 function demonstrated that IL-15ΔE6 activation and function as a negative feedback mechanism to IL-15-mediated inflammatory events [59]. Deubiquitinating enzymes (DUBs) studies have shown emerging as crucial regulators of EAE and MS. Daclizumab, an antibody against the IL-2Rα chain, inhibits brain inflammation in MS [60]. IL-15 improves the CNS autoimmune disorder with a negative regulatory role of IL-17A production. Blockade of IL-15 signaling by TMβ-1 monoclonal antibody (mAb) treatment aggravates EAE severity, suggest that IL-15 activate through CD8+ CD122+ T cells, has a negative regulatory role in reducing IL-17 production [61,62].

**Interleukin-21**

Interleukin-21 (IL-21) is a member of the common gamma-chain-dependent IL-2 cytokine family. IL-21 is a key modulator of lymphocyte development, proliferation, and differentiation. IL-21 is highly expressed in activated CD4 (+) T cells. IL-21r is structurally similar into the receptors for IL-2R or IL-15 binding with the common yc chain to IL-21. It plays a critical role in the expansion and differentiation of the Th17 cell subsets [63].

IL-21 is an autocrine amplification factor, essential for differentiation of Th17 cells, but it does not protect actively induced EAE mice by blocking IL-21 or IL-21 receptor. Th17 cells do transfer EAE but whether the disease is dependent on IL-17 produced by the Th17 cells is not known. It should be noted that the pathogenic capacity of Th17 cells cannot be reduced due to the effects of IL-17 alone but the effects of all cytokines secreted by the Th17 cell subset. Auto reactive purified T cells from IL-21-treated mice, on transfer cells cause more severe EAE than did the control encephalitogenic T cells [64]. NR4A2 appears to control Th17 differentiation.
and so plays an essential role in the development of Th17-mediated autoimmune disease. As NR4A2 is also up-regulated during human autoimmune disease, targeting NR4A2 may provide a new therapeutic approach in treating autoimmune disease. NR4A2 controls Th17 differentiation and plays an essential role in the development of Th17-mediated autoimmune disease in EAE [65].

The IL-21 receptor (IL-21R) consists of a unique subunit and a common γ chain (γc) that is shared with other cytokines of IL-2, IL-4, IL-7, and IL-15. The interaction between IL-21 and IL-21R results in significant effects on both innate and adaptive immune responses. The impact on EAE initiation by IL-21R deficiency was associated with a defect of CD4(+) CD25(+) T regulatory (T reg) cells and a down-regulated expression of Foxp3 [66]. Studies on IL-17 demonstrate γδ T cells, an important source of IL-17 and IL-21 that helped amplify IL-17 production by Th17 cells in autoimmune diseases. IL-17-secreting CD4 T cells (Th17 cells) and IL-17-secreting γδ T cells play a critical pathogenic role in central nervous system (CNS) inflammation in EAE and MS [67].

**IL-21 role in therapy** IL-21 is an essential autocrine amplification factor for differentiation of Th17 cells, the loss of IL-21 or IL-21 receptor (IL-21R) does not protect mice from actively induced EAE. It was demonstrated that DNA vaccination protects from proinflammatory Th17 cell responses during induction of EAE. The mechanism involves IL-17 responses are rescued by silencing of IFN-β during DNA vaccination [68].

Proteoglycans (PGs) are complex glycohydrates proteins. Daily oral administration of PG attenuates the clinical and histological severity in a dose-dependent manner in EAE. Salmon cartilage PG attenuates the severity of EAE by suppressing the differentiation of Th17 lineage and enhancement of Th17 expansion. It has potential involvement of activated Treg and B-cells for the treatment of progressive MS [69]. There is also an interesting study on helminth protein vaccine combined with FK506 induces Tfh cell for stimulating humoral immune responses inducing long-lived humoral immunity. FK506 is an adjuvant for recombinant protein augments the induction of Tfh cells that express IL-21 and IL-4 and produce B cells. FK506 is a widely used immunosuppressant for treating allergies, autoimmune diseases. FK506 as adjuvant of DNA vaccines induced regulatory T cells (Treg) and can prevent MS and other autoimmune disease [70].

**Conclusion**

IL-2 cytokine family members play different roles in demyelinating disease studied in EAE rodent models and in MS patients. Such diversity in role and function keep the immune system changes by developing inflammation and demyelination in the CNS in the initial phase of the disease and back to the normal in the recovery phase. As many therapies are advancing in demyelinating disease, more study is needed to obtain a comprehensive understanding of the entire process, crucial steps and specific time windows for effective therapeutic interventions to suppress disease before reaching at the advance stage. Here are those studies mentioned, including the role of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 played in therapy. The key cytokine roles which govern in therapies make a change in Treg cells and Th17/Th1 paradigm, which allow selecting a choice in demyelinating disease therapy.

**Acknowledgement**

Gratefully acknowledged to Dr. V. K. Mahadik, Director, R. D. Gardi Medical College for the encouragements, and to establish and develop research in biomedical sciences.

**References**


Annals of Immunology & Immunotherapy

Autoimmunity 105: 102300.


29. Ponomarev ED, Maresz K, Tan Y, Dittel BN (2007) CNS-derived interleukin-4 is essential for the regulation...
of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 27(40): 10714-10721.


52. Stephens GL, Swerdlow B, Benjamin E, Coyle AJ, Humbles AA, et al. (2011) IL-9 is a Th17-derived cytokine that limits pathogenic activity in organ-specific autoimmune


